



## Monoclonal Antibody Therapy for COVID-19 Treatment and Prophylaxis

On July 30, 2021, the FDA released an update to the Emergency Use Authorization (EUA) for **REGEN-COV (Casirivimab/Imdevimab)**, manufactured by Regeneron. Below is a recap of the latest information. Note: this information is subject to change.

The only monoclonal antibody currently available to be administered in the long-term care setting, and medication cost covered by the government, is **REGEN-COV (Casirivimab/Imdevimab)**.



For Regeneron Fact Sheet for Health Care Provider and EUA, [click here](#)

<b>REGEN-COV Indications<sup>1</sup></b>	<b>Dosing<sup>1</sup></b>
<b>Treatment of mild to moderate COVID-19</b> in patients who are at high risk to progress to severe COVID-19	600mg Casirivimab/600mg Imdevimab administered as a single dose
<b>Post-exposure prophylaxis of COVID-19 in patients who are:</b> <ul style="list-style-type: none"> <li>- not fully vaccinated <b>or</b> who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination <b>and</b></li> <li>• have been exposed to an individual infected with COVID-19 consistent with close contact <b>OR</b></li> <li>• who are at high risk of exposure to an individual infected with COVID-19 because of occurrence of COVID infection in other individuals in the same institutional setting (e.g., nursing homes)</li> </ul>	<ul style="list-style-type: none"> <li>• <b>IV</b> - Combined in <b>one infusion bag</b> given as a one-time infusion over a minimum of 30 minutes</li> <li>• <b>Subcutaneous (only when IV is not feasible per revised EUA)</b> – Doses of each medication drawn up into four syringes, and administered as four equal 2.5 mL subcutaneous injections</li> </ul>
<b>Ongoing exposure to COVID-19 for longer than 4 weeks</b> (for patients in whom repeat dosing is determined to be appropriate)	<ul style="list-style-type: none"> <li>• <b>Initial dose</b> is 600mg Casirivimab/600mg Imdevimab by subcutaneous injection or intravenous infusion (as above)</li> <li>• Followed by subsequent repeat dosing of 300 mg Casirivimab/300mg Imdevimab by subcutaneous injection or intravenous infusion once every 4 weeks for the duration of ongoing exposure</li> </ul>

**Patient Education:** Review and provide Patient Fact Sheet<sup>2</sup>, [click here](#). Patient consent is needed prior to administration.

For information regarding administration, side effects, monitoring, etc., please see references below. *Omnicare Nursing Procedure 10.18 Administration of Casirivimab/Imdevimab* and supporting documents available on Omniview (e.g., Facility Preparation Checklist/Algorithm, Prescriber Intake/Order Form, Administration Flowsheet)

For additional questions contact your **Omnicare Infusion Pharmacy,**  
**Infusion Nurse Educator, or Consultant Pharmacist**

### References:

1. Casirivimab/Imdevimab Fact Sheet for Healthcare Providers: <https://c212.net/c/link/?t=0&l=en&o=3182647-1&h=3528456854&u=https%3A%2F%2Fwww.regeneron.com%2Fsites%2Fdefault%2Ffiles%2Ftreatment-covid19-eua-fact-sheet-for-hcp.pdf&a=Fact+Sheet+for+Healthcare+Providers>
2. FDA.gov website. Casirivimab/Imdevimab treatment-covid19-eua-fact-sheet-for-patient. <https://c212.net/c/link/?t=0&l=en&o=3182647-1&h=628731868&u=https%3A%2F%2Fwww.regeneron.com%2Fsites%2Fdefault%2Ffiles%2Ftreatment-covid19-eua-fact-sheet-for-patient.pdf&a=Patient+Fact+Sheet>

This is provided for informational and reference purposes only and is based on cited sources existing at the time of review. It does not constitute medical, legal, or regulatory advice and is not a substitute for individualized assessment and treatment by an appropriate medical provider.